glp-1 risks Exploring the Side Effects of Receptor Agonist: To Ensure Its Optimal Positioning Schematic overview of the benefits
Description
Lilly Homepage
A phase 1b clinical trial in Chinese individuals using a MAD study design shows a mean weight loss at 12 weeks of 11.7% at 9 mg, and 9.5% over 16 weeks at 10 mg, versus 1.8% and 3.3% in those who received placebo, respectively (86)
However, the use of medications for obesity, as for other chronic diseases, will likely require life-long treatment, which makes it important to analyze the long-term efficacy, safety, and economic implications of chronic pharmacotherapy
Are you taking a GLP-1 drug and experiencing hair loss
The ecosystem matters
Besides its popularity for weight loss, berberine is also being studied for its effect on diabetes and heart disease risk factors
